Helix Announces Peer-Review Publication of V-DOS47 in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
34
Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

RICHMOND HILL, ONTARIO--(Marketwired - Aug. 22, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the publication of a peered-reviewed V-DOS47 manuscript in "Frontiers in Immunology" journal. V-DOS47 is Helix's second DOS47 development candidate following L-DOS47, which is currently in clinical testing for the treatment of non-small cell lung cancer.

The article, entitled "Development and Characterization of a Camelid Single Domain Antibody-Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2", describes the design and construction of V-DOS47 for breast cancer and other potential indications. The paper can be accessed online at https://doi.org/10.3389/fimmu.2017.00956 .

"We are very pleased to present our V-DOS47 research work through a peer-reviewed forum," said Heman Chao, Ph.D., Chief Executive & Scientific Officer of Helix. "V-DOS47 research and development activities, coordinated by our Polish subsidiary, Helix Immuno-Oncology S.A., have been progressing well. We continue to work closely with our team in Poland to advance the DOS47 platform."

About V-DOS47

V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2). V-DOS47 is the second immuno-oncology drug candidate derived from the Company's DOS47 technology platform. V-DOS47 late phase preclinical and early phase clinical development is supported by a Grant Funding Agreement ("Agreement") with the Polish National Centre for Research and Development and Helix BioPharma Corp.'s wholly subsidiary Helix Immuno-Oncology S.A.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Cautionary Statements

This news release may contain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws including, without limitation, those relating to Helix's operations and strategy and its research and development activities. These statements generally can be identified by forward looking words such as "ongoing", "excited", "efforts", "will" or "modify", and other similar expressions, are intended to provide information about management's current plans and expectations.

Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's priority continuing to be L-DOS47; (iii) the Company's development programs for DOS47, L-DOS47 and V-DOS47; (iv) future expenditures, the insufficiency of the Company's current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix's research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed under Helix's profile on SEDAR at www.sedar.com (together, the "Helix Risk Factors"). Certain material factors, estimates or assumptions have been applied in making forward-looking statements including, without limitation, the safety and efficacy of the Company's drug product candidates; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company's actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.

Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix's management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.

Investor Relations 905 841 2300 905 841 2244 (FAX) ir@helixbiopharma.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lear Gears Up for Goldman Sachs Event Spotlight

Updated Category News Views 132

Lear Prepares for the Big Stage in London Autumn leaves and industry insights are falling in full swing as Lear Corporation gets its ducks in a row for the upcoming Goldman Sachs 18th Annual Industrials & Autos Week. Kicking off on December 3, 2026, this gathering in London isn't just another checkbox on their corporate calendar—it's a prime moment in the spotlight....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 88

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Armada Moves up as Key Player in US SI Exports

Updated Category News Views 121

Pioneering New Grounds in Intelligence Infrastructure Hell of a move by Armada, stepping into the limelight as a priority team leader in the U.S. SI Exports Program. The whole gig is under the Department of Commerce's belt, pushing the frontier of America's Super Intelligence (SI) technology to buddies across the globe. It's like watching the next big blockbuster unfold...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 123

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Kansai Powers Up US Grid with Bold Investment Move

Updated Category News Views 135

Betting Big on Battery Storage Let's unpack this big move by Kansai Electric. Anytime a major player like Kansai steps out of its home turf, folks better pay attention. Looks like Kansai's gotten cozy with Elevate and ArcLight, nabbing a minority stake in Prospect Power. This ain't your average widget factory—it's a beefy 150MW/600MWh battery energy storage facility in...

Continue Reading
Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 100

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading

Top 5 Most Recently Viewed Articles

Protecting Your Rights as a Match Group, Inc. Investor

Updated Category News Views 82

Understanding Your Legal Rights as a Match Group, Inc. Investor Investors in Match Group, Inc. have been notified about an important class action securities lawsuit initiated by Levi & Korsinsky, LLP. This legal action aims to safeguard the interests of investors who might have suffered financial losses due to alleged securities fraud. What is the Class Action Lawsuit...

Continue Reading
Experience Cutting-Edge Communication Solutions at MWC25

Updated Category News Views 449

Hytera Communications at MWC25 Hytera Communications, a leading provider of professional communications technologies and solutions, is excited to announce its participation in the upcoming Mobile World Congress 2025 (MWC25). This prestigious event will take place at the Fira Gran Via in Barcelona. Hytera is eager to showcase its innovative portfolio of mission-critical...

Continue Reading
Home Chef's New Partnership with Giada: What's the Scoop?

Updated Category News Views 241

Home Chef's Flavorful Collaboration This takes me back, ya know? Reminds me of when brands tried to jazz things up with culinary pros. Home Chef, that name's been buzzing around the meal kit world, right? They’ve teamed up with culinary superstar Giada De Laurentiis—an Emmy winner, no less—for an exclusive eight-week menu packed with Italian flair. Like, who...

Continue Reading
Angeles Equity Partners Welcomes Chetan Bhandari as Leader

Updated Category News Views 315

Angeles Equity Partners Enhances Leadership with New Appointment Angeles Equity Partners, a well-regarded private investment firm, announces the addition of Chetan Bhandari as the new Head of Capital Markets within the Angeles Operations Group. Bhandari enters this role equipped with over 30 years of rich experience in the financial sector. His expertise spans advising...

Continue Reading
Investors Alert: Join Ready Capital Corporation Class Action

Updated Category News Views 246

Understanding the Class Action Opportunity for Investors The landscape for investors can often seem daunting, particularly with securities fraud cases disrupting the financial market's integrity. One prominent case currently unfolding involves Ready Capital Corporation, traded under NYSE: RC. A class action lawsuit is underway, which gives affected investors a chance to...

Continue Reading